Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 258Gynecologic 7Tumor-Agnostic 4Other 4Genitourinary 4Thoracic 3Endocrine 3Gastrointestinal 2Other neoplasm 1NET 1Lymphoid 1Head & Neck 1

Conditions

Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 2Tuberous Sclerosis 1Neuroendocrine Tumors 1Hyperglycemia 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
exemestane × Endocrine × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT04300790 2025-07-29

METALLICA

MedSIR

Phase 2 Completed
69 enrolled
BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02753686 2023-02-15

Treat ER+ight

Novartis

Completed
440 enrolled
Endocrine

Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡